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Chemoprevention of DMBA-induced mammary
carcinogenesis in rats by low-dose EPA and DHA
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Summary We investigated the effects of low-dose eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on the incidence and
growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in rats fed a high-fat (HF) diet. We also examined the
effects of these treatments on the fatty acid composition of tumour and serum. Tumour incidence was significantly decreased by the
administration of low-dose EPA and DHA, whereas their inhibitory effects on tumour growth did not reach significance. Serum arachidonic
acid (AA) level was decreased by the administration of low-dose EPA and tended to be decreased by the administration of low-dose DHA,
whereas tumour AA levels were not changed. The administration of low-dose EPA and DHA may be useful for inhibiting the incidence of
breast cancer.
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In recent years, the incidence of breast cancer has increased in
Japan (Tominaga and Kuroishi, 1995), although it is still lower
than in western countries (Tominaga and Kuroishi, 1995). There
has also been a trend towards increased overall mortality from this
disease in Japan over the last decade (Tominaga and Kuroishi,
1995), despite advances in early diagnosis by mammographic
screening and the recognition that appropriate adjuvant chemo-
therapy orhormonal therapy may reduce the risk ofrecurrence and
improve survival (Early Breast Cancer Trialists' Collaborative
Group, 1992). Obviously, approaches to the control of breast
cancer must emphasize both prevention and treatment. It is
mandatory to expand our efforts in identifying the causes ofbreast
cancer and instituting a more effective programme for breast
cancer prevention.
There is an inverse relationship between the incidence ofbreast
cancer and the level of fish consumption, suggesting a protective
role of n-3 polyunsaturated fatty acids (PUFAs) in human breast
cancer (Kaizer et al, 1989). It has been reported that rural Japanese
(Iso et al, 1989) and Greenland Eskimos (Sinclair, 1981), who
exhibit low breast cancer rates, consume a larger amount ofdietary
n-3 PUFAs, compared with high-risk Americans (Sinclair, 1981;
Cohen et al, 1993). Fish oils rich in n-3 PUFAs, mainly eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA), have been
shown to inhibit tumour development in some animal models
(Karmali et al, 1984; Carroll and Braden, 1985a; Jurkowski and
Cave, 1985; Cohen et al, 1993; Kinoshita et al, 1994; Rose et al,
1995). However, several investigators have found that the
inhibitory effect ofn-3 PUFAs was apparent when the n-31n-6 ratio
ranged from 1:1 to 1:2 (Abou-El-Elaet al, 1989; Cohenetal, 1993;
Noguchi et al, 1995a), indicating that the ratio ofn-3 to n-6 PUFAs
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may be more importantthan the total quantity ofn-3 PUFAs.Thus,
n-3 PUFAs have unique properties and a potential role as chemo-
preventive agents in breast cancer, but a large amount of dietary
n-3 PUFAs would be required for breast cancer prevention
and treatment. Nevertheless, the ratio of n-3 to n-6 PUFAs in the
Japanese diet is less than 1:2 (Hirahara, 1995), whereas the
Eskimo diet is unusual in that fat is derived almost exclusively
from fish and aquatic animals. Therefore, it is possible that a rela-
tively low dose of n-3 fatty acid also reduces the incidence of
breast cancer, although it could not inhibit tumourgrowth.
Therefore, in the present study, we investigated whether
low-dose EPA and DHA inhibit the incidence and growth of a
7,12-dimethylbenz(a)-anthracene (DMBA)-induced mammary
carcinoma in rats fed a high-fat diet, and how such effects relate to
observed changes in the chemical content offatty acids in tumour
and serum. One part of the present study has been reported else-
where (Minami and Noguchi, 1996).
MATERIALS AND METHODS
Experimental animals and procedure
Inbred virgin female Sprague-Dawley rats were obtained from the
Shizuoka Laboratory Animal Center (Shizuoka, Japan). They
were maintained on laboratory chow and housed in suspended
metal cages in a temperature- [23 ± 20C (s.e.)] and humidity-
controlled facility on a 12-h light, 12-h dark cycle. At 50 days of
age, rats were given a single dose (5 mg) of DMBA (Sigma
Chemical Co., St Louis, MO, USA) via an intragastric tube. Seven
days after DMBA administration, the rats were switched from
laboratory chow to either a high-fat (20% corn oil) or a low-fat
(0.5% corn oil) diet (Oriental Yeast, Tokyo,Japan). The 90 rats fed
a high-fat diet were then randomly allocated to three groups of30.
Each rat was given 0.5 ml of one of the following oils twice a
week via an intragastric tube throughout the experiment: coconut
oil (CO-HF group), EPA ethyl ester (EPA-HF group) or DHA
ethyl ester (DHA-HF group). The other 30 rats fed a low-fat diet
348Chemoprevention ofmammarycarcinogenesis bylow-dose EPA andDHA 349
Table 1 Effects of high dietary fat, EPA and DHA on tumourigenesis and tumour growth of DMBA-induced mammary carcinoma in rats (means ± s.d.)
(a)CO-HF (b)CO-LF (c)EPA-HF (d)DHA-HF Fisher PLSD
Groups (n=30) (n=28) (n=24) (n=24) P <0.05
Calory in a week (kcal) 256 ± 41 254 ± 35 258 ± 30 257 ± 33 NS
Body weight (g) 261 ± 29 266 ± 30 261 ± 23 261 ± 29 NS
No. of ratswith tumours 24 11 10 6-
Tumour incidence (%) 80 39 42 25 a-b, a-c, a-d
No. of tumours 50 16 15 8
No. of tumours per rat 1.7 ± 1.4 0.6 ± 0.9 0.6 ± 0.8 0.3 ± 0.6 a-b, a-c, a-d
No. of tumours/tumour-bearing 2.1 ± 1.4 1.4 ± 0.8 1.5 ± 0.5 1.3 ± 0.5 a-b, a-c, a-d
rat
Initial tumour weight (g) 3.7 ± 7.9 1.2 ± 2.3 1.6 ± 1.4 1.4 ± 1.4 NS
Average tumour weight (g) 2.4± 5.8 1.0 ± 1.9 1.1 ± 1.2 0.9± 1.2 NS
(all tumours)
Tumour doubling time (days) 15 ± 10 19± 20 23± 12 15± 14 NS
CO-HF, coconut oil-treated high-fat group; CO-LF, coconut oil-treated low-fat group; EPA-HF, eicosapentaenoic acid-treated high-fat group; DHA-HF,
docosahexaenoic acid-treated high-fat group; NS, not significant.
were given 0.5 ml of coconut oil (CO-LF group). Food and water
were available ad libitum until 20 weeks after DMBA administra-
tion. All rats were weighed twice a week, and mean food
consumption was calculated every week. Twenty weeks after
DMBA administration, all rats were killed, and all palpable
tumours were removed. A cardiac blood sample was obtained and
serum was separated by centrifugation (80 xg, 10 min). A portion
of tumour and a serum aliquot were immediately stored at -80°C
for fatty acid measurement. Another part of the tumour was fixed
in 10% formalin. A 5-gm section of each tumour was obtained
from the paraffin block and stained with haematoxylin-eosin for
histological examination. The rats that died before 20 weeks after
DMBA administration were excluded from this study. The
hormone receptor contents of the tumours were not measured in
this study.
Compositions of high-fat and low-fat diets
The compositions ofhigh-fat (20% corn oil) and low-fat (0.5% corn
oil) diets have been reported previously in detail (Noguchi et al,
1991). Briefly, the high-fat diet contained the following (percentage
by weight): corn oil, 20.0; vitamin-free casein, 25.0; a-potato
starch, 10.0; 13-corn starch, 5.25; cellulose powder, 26.75; mineral
mixture, 6.0; vitamin mixture, 2.0; and granulated sugar, 5.0. The
low-fat diet contained the following (percentage by weight): corn
oil, 0.5; vitamin-free casein, 25.0; a-potato starch, 10.0; ,B-corn
starch, 49.125; cellulose powder, 2.375; mineral mixture, 6.0;
vitamin mixture, 2.0; and granulated sugar, 5.0. The mineral
mixture contains in each kg: potassium 4.2 g, phosphorus 9.9 g,
calcium 5.6 g, sodium 2.5 g, magnesium 749 mg,iron 270 mg, zinc
51 mg, manganese 22 mg, copper 5.7 mg and iodine 4.6 mg. The
vitamin mixture contains in each kg: vitamin A acetate 10 000 IU,
vitamin D3 2000 IU, vitamin B1 24 mg, vitamin B2 80 mg, vitamin
B5 16 mg, vitamin B12 0.01 mg, vitamin C 600 mg, vitamin E 100
mg, vitamin K3 104 mg, biotin 0.4 mg, folic acid 4 mg, calcium
pantothenate 100 g, p-aminobenzoic acid 100 mg, niacin 120 mg,
inositol 120 mg and choline chloride 4.0 g. Thus, the diets were
formulated on the assumption that the rats would consume an equal
numberofcalories, vitamins and minerals, butthe rats receiving the
high-fat diet also had a high-fibre diet. The food was stored in
sealed plastic containers in the dark and maintained at4°C.
Purification of eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA)
Purified EPA ethyl ester (purity 99%) and DHA ethyl ester (purity
98%) were prepared as follows: commercial sardine oil (Nippon
Suisan Co., Ltd, Tokyo, Japan) containing 18% of EPA and 12%
of DHA was transethylated in ethanol with sodium ethoxide. An
ethyl ester mixture was introduced into a distillation system
equipped with a column packed with stainless-steel mesh, and a
C20 fatty acid ethyl ester-rich distillate and a C22 fatty acid ethyl
ester-rich distillate were fractionated. EPA ethyl ester and DHA
ethyl ester were separated from the C20 distillate and C22 distillate,
respectively, on an octadecyl silicate column, with methanol used
as the eluting solvent. All solutions contained 0.05% dl-tocopherol
as an antioxidant.
Body weight and tumour measurement
Body weights, tumour incidence and measurements were recorded
weekly throughout the experimental period. Each tumour location
was recorded, and the size was measured with a Vernier caliper in
two perpendicular dimensions. Tumour diameter was calculated by
averaging these two measurements. Weekly tumour measurements
were added foreach rat, and the values were expressedby summing
the average diameterofall tumours for tumour-bearing rats ofeach
group and by summing the average diameterofinitial tumours only
(first palpable tumours) for tumour-bearing rats of each group.
Mammary tumorigenesis was also assessed as the average tumour
number and percentage tumour incidence. Estimated tumour
weight (ETW) ofthe initial tumour was calculated by the following
equation (Gren et al, 1972): ETW = largest diameter x shortest
diameter2/2 mg. Tumour doubling time (Td,) was calculated as
follows (Collins et al, 1956): Td, = tlnl/2(1nV, - lnV0), where t is
the time period between tumour appearance and 20 weeks after
DMBA administration; V, is ETW 20 weeks following DMBA
administration; V0 is ETW at the time oftumour appearance.
Tumour and serum fatty acids
For fatty acid analysis, lipids were first extracted from mammary
tumours (30-250 mg) or serum (1 ml) with chloroform-methanol
by the method of Folch et al (1957). To isolate the phospholipids
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Table 2 Principal fatty acids in tumour cell phospholipid fractions expressed as percentage of the total assayed fatty acid content (means + s.d.)
Groups (a)CO-HF (b)CO-LF (c)EPA-HF (d)DHA-HF Fisher PLSD
(nr6) (n=5) (n=5) (n=5) P<0.05 (P< 0.1)
C14:0 0.8±0.4 0.7+0.1 0.5±0.1 0.7±0.1 NS
C16:0 22.5+ 1.1 22.4 ± 2.6 23.4+ 1.9 24.0 ± 1.6 NS
C16:1 1.5±0.3 2.8±0.3 1.4±0.2 1.5±0.1 a-b,b-c,b-d
C18:0 15.0± 1.4 12.9± 1.0 15.7+ 1.7 14.1 ±1.0 b-d
C18:1 (OL) 15.9+1.4 21.7±1.8 16.2±1.0 16.3+1.2 a-b,b-c,b-d
C18:2 (LA) 4.6 ± 0.6 1.5 +0.5 5.5 ± 0.7 4.7± 0.9 a-b,b-c,b-d
C20:4 (AA) 25.8 ± 2.7 25.2 + 1.1 24.4 ± 1.3 25.6 ± 2.7 NS
C20:5 (EPA) 0.0 + 0.1 0.1 + 0.1 0.9 ± 0.4 0.1 ± 0.1 a-c, b-c, c-d
C22:4 3.5 ± 1.4 2.9 ± 0.3 2.5 ± 0.3 2.8 ± 0.5 NS
C22:5 (DPA) 0.2 ± 0.0 0.3 + 0.2 1.9 ± 0.4 0.4 ± 0.1 a-c, b-c, c-d
C22:6 (DHA) 1.8 + 0.2 1.5 + 0.4 2.1 ± 0.1 3.9 + 0.5 a-d, b-d, c-d, (b-c)
CO-HF, coconut oil-treated high-fat group; CO-LF, coconut oil-treated low-fat group; EPA-HF, eicosapentaenoic acid-treated high-fat group; DHA-HF,
docosahexaenoic acid-treated high-fat group; OL, oleic acid; LA, linoleic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA,
docosahexaenoic acid; AA, arachidonic acid; NS, not significant.
from the neutral lipids, the extracted lipids were exposed to a
thin-layer plate of silica gel G and developed with an n-hexane-
diethylester-acetic acid (50:50:1, v/v/v) solvent system. The phos-
pholipid band at origin was scraped off and phospholipids were
recovered upon extraction with chloroform-methanol (2:1, v/v).
After the removal of solvent under nitrogen, the phospholipids
were transesterified with boron trifluoride-methanol and the
methylesters were analysed by gas chromatography (Hewlett-
Packard 5890A, Hewlett-Packard Co., Palo Alto, CA, USA) using
a fused silica capillary column (Omegawax 320, Supelco,
Bellefonte, PA, USA) (0.32 mm in diameter and 30 m in length)
coated with 0.25-gm-thick Supelcowax 10 (Supelco, Bellefonte,
PA, USA). The column temperature was maintained 185°C for 10
min, then raised to 225°C at a rate of 2°C min-' and maintained at
the final temperature for 5 min. An injection temperature of
2500C, a detector temperature of 270°C and a column flow of 1.2
ml min-' of helium were used. Peaks were determined by a flame
ionization detector and were qualified using a Hewlett Packard
3393A integrator (Hewlett Packard). Identification of each peak
was carried out by the comparison ofretention time with authentic
fatty acid methyl esters. The compositions ofindividual fatty acids
were expressed as the percentage of the total area of all fatty acid
peaks from 14:0 to 22:6.
Statistical analysis
Statistical differences in mammary tumour size, average tumour
number, tumour doubling time, serum and tumour fatty acid
composition were analysed using the Scheffe-type multiple
comparison test. Values ofP < 0.05 were considered significant.
RESULTS
Food intake, body weight and tumour histology
The average amount of feed per rat was 70 g per week.
Consequently, the proportion ofintake ofn-3/n-6 PUFAs in a week
was 1:6.36 in the EPA-HF and DHA-HF groups. The intake ofn-3
PUFAs was minimal in the CO-HF and CO-LF groups. Total body
weight did not differ significantly among the groups of rats
throughout the experimental period. Twenty weeks after DMBA
administration, the mean total body weight was 261 ± 29 g in the
CO-HF group, 266 ± 30 g in the CO-LF group, 261 ± 23 g in the
EPA-HF group and 261 ± 29 g in the DHA-HF group (Table 1).
The induced mammary tumours were histologically identified as
adenocarcinoma. No fibroadenomas were found.
Tumour incidence and growth
Tumour incidence in the CO-HF group, CO-LF group, EPA-HF
group and DHA-HF group was 80%, 39%, 42% and 25% respec-
tively (Table 1). The total number of tumours per rat was about
threefold higher in the CO-HF group than in the CO-LFgroup. The
addition of EPA or DHA to the high-fat diet resulted in
a reduction in the total number of tumours by one-third or one-
sixth respectively. The number of tumours per rat as well as per
tumour-bearing rat was significantly increased in the CO-HF group
compared with the CO-LF, EPA-HF and DHA-HF groups (Table
1). Although the average estimated tumour weight of all tumours
as well as the average estimated tumour weight ofthe first tumour
ofeach rat was increased in the CO-HF group, this difference was
not statistically significant. Moreover, the tumour doubling time
was not statistically different among the groups (Table 1).
Tumour phospholipid fatty acid composition
The administration of EPA and DHA resulted in increased EPA
(20:5) and DHA (22:6) respectively. Oleic acid (OL, 18:1) was
significantly decreased in the CO-HF, EPA-HF and DHA-HF
groups compared with the CO-LF group. Linoleic acid (LA, 18:2)
was significantly increased in the CO-HF, EPA-HF and DHA-HF
groups compared with the CO-LF group. However, arachidonic
acid (AA, 20:4) was not statistically different among the groups
Table 2).
Serum phospholipid fatty acid composition
The administration of EPA and DHA resulted in increased EPA
(20:5) and L-A (22:6) respectively. OL (18:1) was significantly
decreased in the CO-HF, EPA-HF and DHA-HF groups compared
with the CO-LF group. LA (18:2) was significantly increased in
the EPA-HF and DHA-HF groups compared with the CO-LF
group. AA (20:4) was significantly decreased in the EPA-HF
group compared with the CO-HF group (P = 0.011), while it was
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Table 3 Principal fatty acids in serum phospholipid fractions expressed as percentage of the total assayed fatty acid content (means ± s.d.)
Groups (a)CO-HF (b)CO-LF (c)EPA-HF (d)DHA-HF Fisher PLSD
(n=6) (n=5) (n=5) (n=5) P<0.05 (P< 0.1)
C14:0 0.6± 0.2 0.6± 0.2 0.6+ 0.2 0.5± 0.2 NS
C16:0 10.5±1.2 13.3±1.7 12.0±1.5 11.5±0.9 a-b
C16:1 0.9±0.4 2.2±0.9 0.8±0.2 0.9±0.6 a-b, b-c, b-d
C18:0 28.4± 2.1 26.6 ± 2.6 25.6 ± 1.9 26.1 ± 2.3 NS
C18:1 (OL) 4.5 ± 0.6 12.8 ± 2.0 5.9 + 0.4 6.3 + 2.3 a-b, b-c, b-d
C18:2 (LA) 9.9± 4.1 4.7 ± 1.0 14.2 ± 1.9 12.9 ±4.6 b-c, b-d
C20:4 (AA) 26.4 ± 2.2 23.5 ± 3.2 19.3 +3.2 21.4 ± 3.4 a-c, (a-d)
C20:5 (EPA) 0.1 +0.3 0.4±0.3 3.7±2.5 1.8+2.1 a-c, b-c
C22:4 4.5+ 1.4 3.0+ 1.0 1.3 ± 0.7 0.8 ± 0.5 a-c, a-d,b-d, (b-c)
C22:5 (DPA) 0.1 + 0.2 0.2 ± 0.1 2.9 ± 0.5 0.6 + 0.3 a-c, b-c, c-d, (a-d)
C22:6 (DHA) 5.5+1.6 3.4+0.3 5.8±0.7 11.2±1.8 a-d, b-d, c-d, (b-c)
CO-HF, coconut oil-treated high-fat group; CO-LF, coconut oil-treated low-fat group; EPA-HF, eicosapentaenoic acid-treated high-fat group; DHA-HF,
docosahexaenoic acid-treated high-fat group; OL, oleic acid; LA, linoleic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA,
docosahexaenoic acid; AA, arachidonic acid; NS, not significant.
Table 4 Levels of linoleic acid and arachidonic acid, and ratio of arachidonic acid/linoleic acid in tumour and serum (means ± s.d.)
Groups (a)CO-HF (b)CO-LF (c)EPA-HF (d)DHA-HF Fisher PLSD
(n=4 (n=5) (f=4) (n=4) P<0.05
Ratio of tumour LA / serum LA 0.6± 0.1 0.3± 0.1 0.4± 0.1 0.4± 0.2 NS
Ratio of tumour AA/serum AA 1.0+ 0.2 1.1 ± 0.2 1.3+ 0.3 1.3+ 0.2 NS
Ratio of AA / LA in tumour 5.7 ± 1.2 19.1 +8.6 4.5+ 0.8 5.6± 1.3 a-b, b-c, b-d
Ratio of AA / LA in serum 2.9 ± 0.9 5.2 ± 1.5 1.4 ± 0.3 1.9 ± 0.8 a-b,b-c,b-d
CO-HF, coconut oil-treated high-fat group; CO-LF, coconut oil-treated low-fat group; EPA-HF, eicosapentaenoic acid-treated high-fat group; DHA-HF,
docosahexaenoic acid-treated high-fat group; LA, linoleic acid; AA, arachidonic acid; NS, not significant.
insignificantly decreased in the DHA-HF groupcompared with the
CO-HF group (P = 0.098) (Table 3).
Comparison of linoleic acid and arachidonic acid in
tumours and serum
LA levels in serum were consistently higher than tumour levels in
each group. LA levels in tumour and serum were significantly
higher in the CO-HF, EPA-HF and DHA-HF groups compared
with the CO-LF group. The tumour-serum ratio of LA was not
significantly different among the groups (Table 4). Although
tumour AA levels were not different among the groups, AA levels
in serum were decreased in the EPA-HF and the DHA-HF groups
compared with the CO-HF group. Similarly, the tumour-serum
ratio of AA was higher in the DHA-HF and EPA-HF groups than
in the CO-HF and CO-LF groups, although the difference was not
statistically significant (Table 4). The ratio of AA-LA in tumour
and serum was not different among theCO-HF, EPA-HF and DHA
groups, while it was significantly higher in the CO-LF group
compared with the CO-HF, EPA-HF and DHA groups (Table 4).
DISCUSSION
The promotion of carcinogen-induced, spontaneous and trans-
plantable mammary tumours is enhanced in rats fed increasing
concentrations of n-6 PUFAs containing a large amount of
linoleic acid (LA) (Carter etal, 1983; Welsch, 1987; Noguchi et al,
1991), although cohort and case-control studies have generally
been unsuccessful in confirming a strong association between
dietary fat and human breast cancer risk (Goodwin et al, 1987).
Alternatively, diets containing high levels of n-3 PUFAs, mainly
EPA and DHA, have been shown to inhibitdevelopment ofseveral
carcinogen-induced and transplantable cancers (Karmali et al,
1984; Carroll and Braden, 1985a; Jurkowski and Cave, 1985;
Cohen et al, 1993; Kinoshita et al, 1994; Rose et al, 1995). With
regard to the promotive or inhibitory effects of PUFAs, several
authors have drawn attention to the dietary imbalance of n-3 and
n-6 PUFAs (Karmali, 1987a; Karmali et al, 1989; Kromhout,
1990). In experimental studies, it has been reported that the ratio
of n-3 to n-6 PUFAs, rather than the total quantity of n-3 PUFAs,
plays an important role in the inhibition of tumorigenesis by n-3
PUFAs (Abou-El-Ela et al, 1989; Cohen et al, 1993; Noguchi et al,
1995a). In an in vivo study, Abou-El-Ela et al (1989) have found
that a diet containing an n-3/n-6 PUFA ratio of 1:2 reduced
DMBA-induced mammary tumorigenesis. Moreover, in other in
vivo studies, lower levels of dietary n-3 fatty acids either had no
effect or enhanced mammary tumour development (Carroll and
Braden, 1985b; Jurkowski and Cave, 1985; Cohen et al, 1993).
Also, in an in vitro study (Noguchi et al, 1995a), cell proliferation
of human breast cancer cells (MDA-MB-231) was inhibited at a
DHA-LA ratio of 1:2.08 and at an EPA-LA ratio of 1:0.69, while
a lower ratio of n-31n-6 PUFAs did not enhance cell proliferation.
Thus, n-3 PUFAs have unique properties and a potential role as
chemopreventive agents in breast cancer, but a large amount of
dietary n-3 PUFAs would be required for breast cancer prevention
and treatment.
It has been reported that Greenland Eskimos (Sinclair, 1981),
who exhibit low breast cancer rates, consume PUFAs with n-31n-6
ratios of 1:0.36 compared with high-risk Americans, who consume
PUFAs with an n-3/n-6 ratio of approximately 1:8.33 (Sinclair,
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1981; Cohen et al, 1993). The Eskimo diet is clearly unusual in
that fat is derived almost exclusively from fish and aquatic
mammals and is therefore rich in n-3 PUFAs. However, an
epidemiological study has demonstrated that the Japanese, who
also exhibit low breast cancer rates, consumed PUFAs with n-31n-
6 ratios ranging from 1:4.26 to 1:4.20 between 1971 and 1980
(Hirahara, 1995). It is apparent that an n-31n-6 PUFA ratio of less
than 1:2 is still effective in reducing the incidence ofbreast cancer.
In the present study, EPA and DHA were given at the n-3/n-6
PUFA ratio of 1:6.36. Consequently, tumour incidence was
decreased by the administration oflow-dose EPA and DHA, while
their inhibitory effects on tumour growth did not reach signifi-
cance. There is an apparent discrepancy between the results ofthe
present study and previous experimental studies (Carroll and
Braden, 1985b; Jurkowski and Cave, 1985; Cohen et al, 1993).
While n-3 PUFAs were provided in food in the previous in vivo
studies, they were given twice weekly as a drug with an n-3/n-6
PUFA ratio of 1:1.82 in the present study. It would be ofinterest to
investigate how such effects relate to observed changes in the
chemical content offatty acids in tumour and serum.
Several studies have been undertaken to investigate the influ-
ence of n-3 PUFAs on the composition of fatty acids in tumours
(Karmali et al, 1984, 1989; Jurkowski and Cave, 1985; Takata et
al, 1990; Rose et al, 1995) and in plasma or serum (Abou-El-Ela et
al, 1988; Cohen et al, 1993). They have demonstrated a decrease in
AA in tumours and serum from animals fed fish oil, a source rich
in EPA and DHA. Both EPA and DHA may exert their effects by
competing with arachidonic acid (AA), thereby diminishing the
formation of AA metabolites (Karmali, 1987a,b). It has been
reported that fish oil lowers the activity of A5 and A6 desaturases
in rodents (Hagve and Christophersen, 1984; Juan and Sametz,
1985; Garg et al, 1988). Takata etal (1990) have suggested that LA
is increased and AA is decreased by the inhibition of A5 and A6
desaturases. Karmali et al (1984) have demonstrated that the ratio
ofAA to LA may be an important factor for mammary tumorigen-
esis. In the present study, LA levels in tumour and serum were
increased by the intake of a HF diet, but not by the administration
of low-dose EPA and DHA. AA levels in tumour and serum were
not altered by a HFdiet, although serum, but not tumour, AA level
was decreased by the administration of low-dose EPA and tended
to be decreased by the administration oflow-dose DHA. It is likely
that AA metabolism in serum plays an important role in mammary
tumorigenesis, although the ratio of AA to LA in tumour and
serum was not associated with tumour incidence. An epidemiolog-
ical study has demonstrated that serum AA was decreased and
serum LA was increased in Japanese compared with Americans
(Iso et al, 1989).
AA-derived eicosanoids are believed to play an important role
in these processes of tumorigenesis and tumour proliferation
(Carter et al, 1983; Noguchi et al, 1995c). However, it is important
to distinguish the mechanisms that underly tumorigenesis and
tumour proliferation (Noguchi et al, 1991, 1995b). In the present
study, DHA was more active than EPA in reducing tumour inci-
dence, although EPA was more active than DHA in reducing
serum AA levels, findings compatible with the study ofTerano et
al (1987). Although EPA is a competitive inhibitor of both the
cyclo-oxygenase and lipoxygenase pathways (Karmali, 1987b),
DHA is a strong inhibitor ofprostaglandin synthesis (Corey et al,
1983). Nevertheless, DHA can be retroconverted to EPA in vivo
(Terano et al, 1987) and in vitro (de Antueno et al, 1989). In in
vitro studies, it has been reported that DHA is more active than
EPA in reducing PGE secretion (Noguchi et al, 1995a; Rose et al,
1995), while EPA is more active than DHA in reducing LTB secre-
tion (Noguchi et al, 1995a). Prostaglandins play a role in the regu-
lation of both humoral and cell-mediated immunity (Goldyne and
Stobo, 1981). It has been shown that prostaglandins exert an
inhibitory effect on natural killer cells, components of the host
defence system, which are thought to play a role in immunosur-
veillance (Brunda et al, 1980). Tumorigenesis has been suggested
as being inhibited by the decreased production ofimmunosuppres-
sive prostaglandins (Carter et al, 1983; McCormick et al, 1985;
Noguchi et al, 1991). Therefore, it appears that DHA is more
active than EPA in inhibiting mammary tumorigenesis by inter-
fering with prostaglandin metabolism.
Low-dose EPA and DHA completely blocked the stimulatory
effect of fat on tumour incidence in the present study, while their
inhibitory effects on tumour growth did not reach significance.
Therefore, relatively low-dose EPA and DHA may be useful for
breast cancerprevention. However, this study was performed in an
experimental carcinogenesis model. Ip (1993) has stated that fat
promotes mammary carcinogenesis only under a very stringent set
of conditions, which might not be duplicated in the arena of fat
intake and human breast cancer risk. Further analysis to investi-
gate the mechanisms of the inhibitory effects of EPA and DHA
would considerably strengthen this work.
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